Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病或者更安全的T2DM治，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治，早由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给治性腰椎间盘突出症(LDH)的近远期效果并探讨其治机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早阿司利康公司开发的长效的口服非甾体结构的雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病或者更安全的T2DM，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的甾体结构的抗雄激药物，1995年在英国首次。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM疗药，给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM疗药，给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病或者更安全的T2DM，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其。